| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Michael P. Lisanti | Q77913186 |
| P2093 | author name string | Chenguang Wang | |
| D Joshua Liao | |||
| Yanhong Tai | |||
| P2860 | cites work | c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression | Q73383736 |
| Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis | Q73540242 | ||
| Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability | Q74752133 | ||
| A matter of life and cell death | Q77164675 | ||
| Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration | Q77769534 | ||
| Cell Death in MMTV-c-myc Transgenic Mouse Mammary Tumors May Not Be Typical Apoptosis | Q79176341 | ||
| The scavenger cell hypothesis of apoptosis: apoptosis redefined as a process by which a cell in living tissue is destroyed by phagocytosis | Q81746515 | ||
| Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma | Q82193149 | ||
| Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo | Q82606388 | ||
| Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts | Q24290150 | ||
| A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation | Q24314746 | ||
| Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response | Q24616966 | ||
| c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL | Q24653312 | ||
| Developmental context determines latency of MYC-induced tumorigenesis | Q24794847 | ||
| CytoregR inhibits growth and proliferation of human adenocarcinoma cells via induction of apoptosis | Q25255979 | ||
| MYC is a metastasis gene for non-small-cell lung cancer | Q27347283 | ||
| Proliferation, cell cycle and apoptosis in cancer | Q28189476 | ||
| c-MYC: more than just a matter of life and death | Q28205057 | ||
| Repression of p15INK4b expression by Myc through association with Miz-1 | Q28210023 | ||
| Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin | Q28220621 | ||
| The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis | Q28240820 | ||
| The great MYC escape in tumorigenesis | Q28272812 | ||
| Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells | Q28294137 | ||
| Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 | ||
| Myc deletion rescues Apc deficiency in the small intestine | Q28591197 | ||
| Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis | Q28593886 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis | Q30417762 | ||
| c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations | Q31929763 | ||
| Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis | Q33344462 | ||
| Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure | Q33506647 | ||
| Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation | Q33591386 | ||
| E2F2 suppresses Myc-induced proliferation and tumorigenesis. | Q33618472 | ||
| Myc suppression of Nfkb2 accelerates lymphomagenesis | Q33624136 | ||
| MYC oncogenes and human neoplastic disease | Q33667340 | ||
| Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy | Q37058068 | ||
| Promotion of hepatocarcinogenesis in humans and animal models | Q37060367 | ||
| Liver repopulation and carcinogenesis: two sides of the same coin? | Q37102829 | ||
| Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas | Q37118264 | ||
| The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse | Q37150786 | ||
| Oncogene addiction | Q37152445 | ||
| The microenvironments of multistage carcinogenesis | Q37154505 | ||
| Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells | Q37167261 | ||
| C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine | Q37204555 | ||
| Comparative aspects of animal regeneration | Q37206211 | ||
| Cell competition and its possible relation to cancer | Q37218503 | ||
| Apoptosis-induced compensatory proliferation. The Cell is dead. Long live the Cell! | Q37251077 | ||
| c-Myc: linking transformation and genomic instability | Q37264779 | ||
| Tumor dormancy and oncogene addiction | Q37286246 | ||
| Apoptotic signaling by c-MYC. | Q37310199 | ||
| The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies | Q37326072 | ||
| Reflecting on 25 years with MYC. | Q37333643 | ||
| Super competition as a possible mechanism to pioneer precancerous fields | Q37363575 | ||
| Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential | Q37364112 | ||
| Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation | Q37375814 | ||
| Facilitating replication under stress: an oncogenic function of MYC? | Q37492244 | ||
| Apoptosis and cancer: the genesis of a research field | Q37529250 | ||
| Myc--what we have learned from flies. | Q37550621 | ||
| Deregulation of cell death (apoptosis): implications for tumor development. | Q37605266 | ||
| ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence | Q37618297 | ||
| Drosophila Myc. | Q37621011 | ||
| Myc's secret life without Max. | Q37627095 | ||
| Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene | Q37631754 | ||
| The ups and downs of Myc biology | Q37644952 | ||
| Bim is a suppressor of Myc-induced mouse B cell leukemia | Q37647369 | ||
| Cellular adaptation in the origin and development of cancer | Q37717278 | ||
| Cdk2: a key regulator of the senescence control function of Myc. | Q37743042 | ||
| Tipping the balance: Cdk2 enables Myc to suppress senescence | Q37780375 | ||
| Nfkb 1 is dispensable for Myc-induced lymphomagenesis | Q38325314 | ||
| Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc | Q39126564 | ||
| Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice | Q39639180 | ||
| Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. | Q54004293 | ||
| Myc heterozygosity attenuates the phenotypes of APC deficiency in the small intestine. | Q54390813 | ||
| Myc and a Cdk2 senescence switch. | Q54702401 | ||
| Myc, Cdk2 and cellular senescence: Old players, new game | Q58883584 | ||
| New principle for the analysis of chemical carcinogenesis | Q59089097 | ||
| PIM1 and MYC: a changing relationship? | Q63407027 | ||
| Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3beta-mediated cyclin D1 overexpression | Q64387135 | ||
| Role for Bcl-xL in the regulation of apoptosis by EGF and TGF beta 1 in c-myc overexpressing mammary epithelial cells | Q71657386 | ||
| Cell proliferation as a major risk factor for cancer: a concept of doubtful validity | Q71974064 | ||
| Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice | Q73078503 | ||
| Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors | Q73099094 | ||
| Point Mutations in c-Myc Uncouple Neoplastic Transformation from Multiple Other Phenotypes in Rat Fibroblasts | Q33742040 | ||
| More than one way to die: apoptosis, necrosis and reactive oxygen damage | Q33807850 | ||
| Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis | Q33810358 | ||
| Action of Myc in vivo - proliferation and apoptosis | Q33840451 | ||
| Apoptosis in cancer | Q33846227 | ||
| The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers | Q33882357 | ||
| Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer | Q33890758 | ||
| c-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium | Q33925138 | ||
| c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points | Q33958488 | ||
| The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals | Q33963949 | ||
| c-Myc in breast cancer | Q34055118 | ||
| Specific protection against breast cancers by cyclin D1 ablation | Q34082446 | ||
| Human c-Myc isoforms differentially regulate cell growth and apoptosis in Drosophila melanogaster | Q34124162 | ||
| You Don't Muck with MYC | Q34157211 | ||
| MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms | Q34248882 | ||
| Myc Function in Drosophila | Q34291633 | ||
| Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance | Q34314752 | ||
| Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice | Q34342812 | ||
| Apoptosis, Stem Cells, and Tissue Regeneration | Q34346968 | ||
| Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice | Q34380431 | ||
| Translocations involving c-myc and c-myc function | Q34405431 | ||
| The resistance phenotype in the development and treatment of cancer | Q34571823 | ||
| Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally | Q34613693 | ||
| Cyclin D1 promotes anchorage-independent cell survival by inhibiting FOXO-mediated anoikis | Q34764094 | ||
| Distinct thresholds govern Myc's biological output in vivo | Q34897529 | ||
| Paradoxical role of apoptosis in tumor progression | Q35014280 | ||
| Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice | Q35016285 | ||
| Identification of CDK4 as a target of c-MYC. | Q35051802 | ||
| Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion | Q35107957 | ||
| Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis | Q35131418 | ||
| Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. | Q35133764 | ||
| Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis | Q35208288 | ||
| c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets | Q35212190 | ||
| c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. | Q35222270 | ||
| Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis | Q35591569 | ||
| Functional link between Myc and the Werner gene in tumorigenesis. | Q35601075 | ||
| Programmed cell death and its protective role with particular reference to apoptosis | Q35623794 | ||
| Multiple cell death pathways as regulators of tumour initiation and progression. | Q35743092 | ||
| Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci | Q35748053 | ||
| Cancer cell biology: Myc wins the competition | Q35795366 | ||
| Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma | Q35828796 | ||
| Bcl-2 protein expression and long-term survival in breast cancer | Q35834034 | ||
| MYC levels govern hematopoietic tumor type and latency in transgenic mice | Q35848951 | ||
| Apoptosis in the development and treatment of cancer | Q35890843 | ||
| Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation | Q35928960 | ||
| Intrinsic tumour suppression | Q35953133 | ||
| The wild-type Ras: road ahead | Q36022672 | ||
| Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis | Q36024052 | ||
| Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants | Q36142180 | ||
| Myc, cell competition, and compensatory proliferation | Q36215291 | ||
| Differential modulation of cyclin gene expression by MYC | Q36258572 | ||
| Soluble factors mediate competitive and cooperative interactions between cells expressing different levels of Drosophila Myc. | Q36276873 | ||
| Antimalarial therapy prevents Myc-induced lymphoma | Q36287308 | ||
| Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. | Q36288668 | ||
| c-myc expression: keep the noise down! | Q36305373 | ||
| C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent | Q36380929 | ||
| A growth-constrained environment drives tumor progression invivo | Q36524341 | ||
| Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy | Q36559283 | ||
| Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models | Q36575307 | ||
| Conditional transgenic models define how MYC initiates and maintains tumorigenesis | Q36578360 | ||
| Repression of cyclin D1: a novel function of MYC | Q36654990 | ||
| Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors | Q36668724 | ||
| Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2 | Q36678903 | ||
| c-myc reverses neu-induced transformed morphology by transcriptional repression | Q36680741 | ||
| Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice | Q36695757 | ||
| Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer | Q36759171 | ||
| Targeting the death machinery in mammary epithelial cells: Implications for breast cancer from transgenic and tissue culture experiments. | Q36866713 | ||
| Drosophila SPARC is a self-protective signal expressed by loser cells during cell competition. | Q39643477 | ||
| Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues | Q39757012 | ||
| Cdk2 suppresses cellular senescence induced by the c-myc oncogene. | Q39763259 | ||
| Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation | Q39774238 | ||
| The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. | Q39821427 | ||
| Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line | Q39895392 | ||
| Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes | Q39904679 | ||
| Identification of the cyclin D1b mRNA variant in mouse | Q39986947 | ||
| Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators | Q39988132 | ||
| Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc. | Q40078195 | ||
| c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells | Q40138478 | ||
| C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma | Q40185161 | ||
| CDK2 is required by MYC to induce apoptosis | Q40270196 | ||
| Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line | Q40382268 | ||
| Transforming growth factor-alpha inhibits the intrinsic pathway of c-Myc-induced apoptosis through activation of nuclear factor-kappaB in murine hepatocellular carcinomas | Q40392805 | ||
| Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity | Q40397713 | ||
| The activities of cyclin D1 that drive tumorigenesis | Q40571080 | ||
| c-myc induces autophagy in rat 3Y1 fibroblast cells. | Q40638488 | ||
| Cell proliferation and apoptosis in normal liver and preneoplastic foci | Q40662457 | ||
| BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases | Q40691704 | ||
| Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. | Q40731052 | ||
| Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. | Q40769247 | ||
| Identification of c-myc responsive genes using rat cDNA microarray. | Q40841505 | ||
| Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. | Q40893166 | ||
| X-gene product of hepatitis B virus induces apoptosis in liver cells | Q41067693 | ||
| Liver regeneration versus direct hyperplasia. | Q41073460 | ||
| Mediation of c-Myc-induced apoptosis by p53. | Q41441186 | ||
| Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. | Q41714456 | ||
| Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation. | Q42006448 | ||
| Ratcheting Myc. | Q42279416 | ||
| Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation | Q42513679 | ||
| The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice | Q42651224 | ||
| Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose | Q42845702 | ||
| Myc lacks E2F1's ability to suppress skin carcinogenesis | Q43728206 | ||
| Can loss of apoptosis protect against cancer? | Q46161155 | ||
| Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms | Q46918938 | ||
| Drosophila myc regulates organ size by inducing cell competition | Q47071644 | ||
| dMyc transforms cells into super-competitors | Q47072112 | ||
| Induction of apoptosis by Drosophila Myc. | Q47072146 | ||
| Early work on the function of Bcl-2, an interview with David Vaux | Q47670135 | ||
| The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo | Q48074944 | ||
| Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice | Q49230994 | ||
| Persistent sex differences in growth control of early rat liver lesions are programmed during promotion in the resistant hepatocyte model. | Q51028514 | ||
| Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape. | Q51800297 | ||
| Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. | Q52177994 | ||
| The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. | Q52207180 | ||
| Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells. | Q52581219 | ||
| Is cell competition relevant to cancer? | Q52687651 | ||
| Myc, Cdk2 and cellular senescence: Old players, new game. | Q53302314 | ||
| Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis. | Q53347808 | ||
| Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha. | Q53401440 | ||
| Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. | Q53439560 | ||
| Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. | Q53442937 | ||
| Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations. | Q53515470 | ||
| Conditional deletion of c-myc does not impair liver regeneration. | Q53620103 | ||
| P433 | issue | 7 | |
| P921 | main subject | carcinogenesis | Q1637543 |
| cell death | Q2383867 | ||
| P304 | page(s) | 615-626 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis | |
| P478 | volume | 11 |
| Q42863365 | Apoptosis in Living Animals Is Assisted by Scavenger Cells and Thus May Not Mainly Go through the Cytochrome C-Caspase Pathway |
| Q38613512 | Axin1 up-regulated 1 accelerates stress-induced cardiomyocytes apoptosis through activating Wnt/β-catenin signaling |
| Q51560902 | C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling. |
| Q36055039 | Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections |
| Q36010516 | Complex Behavior of ALDH1A1 and IGFBP1 in Liver Metastasis from a Colorectal Cancer |
| Q35142978 | Complex alternative splicing of the smarca2 gene suggests the importance of smarca2-B variants |
| Q39931378 | Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-κB and Bcl-2 families |
| Q38734795 | Different N-terminal isoforms of Oct-1 control expression of distinct sets of genes and their high levels in Namalwa Burkitt's lymphoma cells affect a wide range of cellular processes |
| Q57178204 | Endorsing cellular competitiveness in aberrant epithelium of oral submucous fibrosis progression: neighbourhood analysis of immunohistochemical attributes |
| Q59132736 | Evaluating the Remote Control of Programmed Cell Death, with or without a Compensatory Cell Proliferation |
| Q90746119 | Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology |
| Q37626733 | Expression and function of a novel isoform of Sox5 in malignant B cells. |
| Q47652297 | Glycolysis promotes caspase-3 activation in lipid rafts in T cells |
| Q92382697 | Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells |
| Q42236265 | Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutations |
| Q85474858 | Knockdown of dishevelled-1 attenuates cyclosporine A-induced apoptosis in H9c2 cardiomyoblast cells |
| Q36051061 | Liver hyperplasia after tamoxifen induction of Myc in a transgenic medaka model |
| Q38795442 | Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies |
| Q28652643 | Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions |
| Q54976480 | Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer. |
| Q35860856 | Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. |
| Q38125132 | Polycomb group proteins and MYC: the cancer connection. |
| Q37259128 | Regulation of breast cancer and bone metastasis by microRNAs |
| Q28567865 | Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1 |
| Q42444842 | Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing |
| Q34879429 | The Mitoscriptome in Aging and Disease. |
| Q26865888 | The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis |
| Q64974084 | The role of circadian clock genes in tumors. |
| Q38007911 | The voyage of stem cell toward terminal differentiation: a brief overview |
| Q26746180 | The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption |
| Q50052746 | There are only four basic modes of cell death, although there are many ad-hoc variants adapted to different situations |
| Q28533891 | Transcriptome analyses of inhibitor-treated schistosome females provide evidence for cooperating Src-kinase and TGFβ receptor pathways controlling mitosis and eggshell formation |
| Q26781102 | Weaknesses and Pitfalls of Using Mice and Rats in Cancer Chemoprevention Studies |
Search more.